Ibrutinib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma
Status:
Completed
Trial end date:
2017-05-11
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of ibrutinib when given together
with rituximab, ifosfamide, carboplatin, and etoposide (combination chemotherapy) in treating
patients with diffuse large B-cell lymphoma (DLBCL) that has returned after a period of
improvement (relapsed) or has not responded to treatment (refractory). Ibrutinib may stop the
growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in
chemotherapy, such as, rituximab, ifosfamide, carboplatin, and etoposide, work in different
ways to stop the growth of cancer cells, either by killing the cells, by stopping them from
dividing, or by stopping them from spreading. Giving ibrutinib together with combination
chemotherapy may be a better treatment for patients with relapsed or refractory DLBCL.